Haemophilus influenza type b conjugate vaccine

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Haemophilus Influenzae Type B Infection

Conditions

Haemophilus Influenzae Type B Infection

Trial Timeline

Aug 1, 2011 → Jul 1, 2012

NCT ID

NCT01404962

About Haemophilus influenza type b conjugate vaccine

Haemophilus influenza type b conjugate vaccine is a approved stage product being developed by Novartis for Haemophilus Influenzae Type B Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01404962. Target conditions include Haemophilus Influenzae Type B Infection.

What happened to similar drugs?

1 of 8 similar drugs in Haemophilus Influenzae Type B Infection were approved

Approved (1) Terminated (0) Active (7)

✅Vaxelis + PedvaxHIBMerckApproved

🔄Comparator: Modified Process Vaccine + Comparator: COMVAX™MerckPhase 3

🔄Haemophilus influenzae type b (Hib) vaccineNovartisPhase 3

🔄Hib-CRM197 + Hib-TTNovartisPhase 3

🔄Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine) + Hiberix (Haemophilus influenzae type b (Hib) vaccine)NovartisPhase 3

🔄Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib) + Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)NovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01404962	Approved	Completed	Aug 1, 2011	Jul 1, 2012	Haemophilus Influenzae Type B Infection

Competing Products

10 competing products in Haemophilus Influenzae Type B Infection

See all competitors

Product	Company	Stage	Hype Score
Comparator: Modified Process Vaccine + Comparator: COMVAX™	Merck	Phase 3	40
Vaxelis + PedvaxHIB	Merck	Approved	43
Haemophilus influenzae type b (Hib) vaccine	Novartis	Phase 3	40
Haemophilus influenzae type b (Hib) vaccine	Novartis	Phase 3	40
Hib-CRM197 + Hib-TT	Novartis	Phase 3	40
Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine) + Hiberix (Haemophilus influenzae type b (Hib) vaccine)	Novartis	Phase 3	40
Haemophilus influenzae type b	Novartis	Phase 1	29
Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib) + Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)	Novartis	Phase 3	40
Haemophilus influenzae type b vaccine + Commercial Haemophilus influenzae type b vaccine	Novartis	Phase 3	40
DTaP-IPV/Hib	Sanofi	Pre-clinical	26